LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the publication of a manuscript detailing long-term outcomes for molgramostim inhalation solution in patients with autoimmune pulmonary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback